Investment will strengthen ACUVUE® contact lens manufacturing, packaging and distribution operations while supporting 3,500 Jacksonville employees
JACKSONVILLE, Fla. (June 15, 2026) — Johnson & Johnson announced plans to invest more than $1 billion in Jacksonville, Florida, to expand and strengthen its U.S. Vision operations, including advanced manufacturing and packaging technologies and a new state-of-the-art distribution facility.
The major investment will support the company’s ACUVUE® brand contact lens operations, enhance supply chain resilience and increase capacity to meet growing demand for vision care products serving more than 40 million patients in the U.S. and around the world.
The project is part of Johnson & Johnson’s previously announced $55 billion commitment to U.S. manufacturing, research and development, and technology through early 2029. Construction is already underway, with the new facility expected to be fully operational in 2028.
Strengthening U.S. Vision Care Manufacturing
The Jacksonville investment will expand Johnson & Johnson’s domestic manufacturing, packaging and distribution capabilities for its market-leading ACUVUE® contact lenses. The company currently manufactures more than 1.7 billion ACUVUE® contact lenses annually for U.S. patients.
Project highlights include:
- More than $1 billion invested in Jacksonville, Florida
- New advanced manufacturing and packaging technologies
- A new state-of-the-art distribution facility
- Expanded U.S. capacity for ACUVUE® contact lenses
- Support for 3,500 Johnson & Johnson employees in Jacksonville
- Continued growth of the company’s $6 billion annual economic impact in Florida
“This investment reinforces our long-standing conviction that advanced manufacturing in the United States is essential to delivering innovative, high quality healthcare solutions to patients at home and around the world,” said Joaquin Duato, Chairman and Chief Executive Officer of Johnson & Johnson. “By further strengthening our Vision operations in Jacksonville with next-generation manufacturing, packaging and distribution capabilities, we are enhancing the resilience of our U.S. supply chain while helping more people see better and live better. This commitment reflects the confidence we have in our people, our technology, and our more than 40-year legacy of advancing eye health globally.”
Jacksonville’s Growing Role in Advanced Manufacturing and Life Sciences
Johnson & Johnson has operated in Jacksonville for more than 40 years, establishing the region as a key hub for vision care innovation and advanced manufacturing. Since first locating in Jacksonville in 1981, the company has grown to occupy more than 1.5 million square feet of manufacturing, research, distribution and operations space.
The expansion further strengthens Northeast Florida’s position as a competitive location for healthcare manufacturing, supply chain operations and life sciences investment.
“Johnson & Johnson’s commitment is a strong vote of confidence in Jacksonville, our workforce, and our future,” said Jacksonville Mayor Donna Deegan. “Jacksonville continues to lead in advanced manufacturing and life sciences innovation. This expansion strengthens our high-tech footprint while creating quality jobs and long-term opportunities for our community.”
State and Federal Leaders Applaud the Investment
U.S. Senator Rick Scott said the investment will help strengthen America’s healthcare supply chain and expand domestic capacity for critical healthcare products.
“Florida continues to play a leading role in strengthening America’s healthcare supply chain to better serve patients,” said Sen. Scott. “The billion-dollar investment in Jacksonville will help expand the domestic capacity and strengthen America’s healthcare infrastructure. That means more jobs in Florida, a stronger national economy, less reliance on foreign healthcare products, and better results for our nation’s long-term health and competitiveness.”
U.S. Senator Ashley Moody said the project reflects Florida’s continued momentum as a destination for business growth and investment.
“I am thrilled to see this major $1 billion investment in our state, funding new state of the art facilities and supporting jobs in the Jacksonville area,” said Sen. Moody. “This is more than simple investment – this represents a down payment on the future of Jacksonville and the state of Florida. Companies are moving to Florida in droves, and massive investment such as this highlights Florida as the nation’s top state to grow your family and your business.”
U.S. Representative John Rutherford noted that Johnson & Johnson’s continued investment reflects the region’s strength in advanced manufacturing and critical healthcare production.
“Johnson & Johnson’s continued investment in Jacksonville reflects the region’s strength in advanced manufacturing and critical healthcare production,” said Rep. Rutherford. “It supports a skilled workforce, strengthens domestic capacity, and reinforces Northeast Florida’s role in keeping America economically competitive.”
U.S. Representative Aaron Bean said the project will create long-term economic benefits for Northeast Florida while strengthening the healthcare supply chain.
“Johnson & Johnson’s $1 billion investment in Jacksonville will strengthen the supply chain for critical vision products while creating high-quality jobs and generating significant economic benefits for Northeast Florida,” said Rep. Bean. “The project reinforces Jacksonville’s status as a premier destination for healthcare manufacturing and innovation, helping ensure the region remains at the forefront of supporting patients and advancing medical technology.”
A Longstanding Legacy of Vision Care Innovation
Johnson & Johnson’s Jacksonville operations have played a major role in advancing eye health for more than four decades. The company’s Vision business has helped transform how patients access and experience optical solutions through continued investment in research, manufacturing and product innovation.
The latest investment will build on that legacy by modernizing operations, expanding U.S. production capacity and strengthening the company’s ability to deliver high-quality contact lenses to patients worldwide.
About Johnson & Johnson
At Johnson & Johnson, health is everything. The company’s strength in healthcare innovation empowers it to build a world where complex diseases are prevented, treated and cured, where treatments are smarter and less invasive, and solutions are personal. Through its expertise in Innovative Medicine and MedTech, Johnson & Johnson is positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity.
For more information, visit www.jnj.com.
